CONTACT
+91 80 2808 2808
info@biocon.com

Business Continuity Statement

 

Biocon & Biocon Biologics ensuring manufacturing of life-saving medicines for patients, partners and customers

Essential Staffing Ensures Business Continuity, Rest ‘Work from Home’ in Compliance with the Government of India directive for COVID-19

Biocon Ltd. and Biocon Biologics have activated business continuity plans across their functions to prepare for unforeseen events, in light of the evolving COVID-19 situation and to meet the needs of patients, partners, customers and other stakeholders who depend on our products.

As a global Company, we have presence across India, UAE, Malaysia, Singapore, Europe, U.S. and are adjusting our operations to fully comply with regulations issued by respective national governments.

The Company is continuously assessing risk factors through a robust business continuity plan and will continue to operate essential pharmaceutical manufacturing, in full compliance with government requirements.

Chairperson Kiran Mazumdar-Shaw said, “As a globally recognised biopharmaceuticals company engaged in innovative science to develop new drugs and manufacturing life-saving therapies, we have a significant role to play in the global pharma ecosystem. We are dealing with unprecedented challenges related to COVID-19 and at the same time we are engaged in several initiatives spanning diagnostic tests, vaccines and therapies towards combating COVID-19. We are confident that together with our teams and partners we will assure safe and uninterrupted manufacturing and enable access to our life-saving medicines despite the current challenges.”

Since we are involved in manufacturing of essential drugs, we continue with manufacturing operations of essential pharmaceuticals, biopharmaceuticals and APIs in order to meet our commitments to patients, customers and partners.

Employee safety is paramount for us at Biocon and we are proud to have maintained an infection-free environment in all our sites. It has enabled us to carry out normal manufacturing operations. Detection of any infection related to COVID-19 in an employee or a set of employees in the future can lead to hampering of our normal manufacturing operations. While we do not envisage shutting down operations, the said manufacturing unit would be sanitised as per protocol, and operations would be restarted.

We remain committed to the health and safety of our employees and their families, as well as, business continuity to safeguard the interests of our patients, partners, customers and other stakeholders.

Share
Previous Next
Close
Test Caption
Test Description goes like this